Estrella Immunopharma, Inc. (NASDAQ:ESLA) Short Interest Update

Estrella Immunopharma, Inc. (NASDAQ:ESLA) was the recipient of a large growth in short interest in the month of November. As of November 30th, there was short interest totalling 37,700 shares, a growth of 158.2% from the November 15th total of 14,600 shares. Currently, 0.4% of the shares of the stock are sold short. Based on an average trading volume of 137,400 shares, the days-to-cover ratio is presently 0.3 days.

Estrella Immunopharma Stock Performance

Shares of NASDAQ ESLA traded down $0.04 during trading on Friday, hitting $1.19. 3,577 shares of the company were exchanged, compared to its average volume of 75,987. Estrella Immunopharma has a 12-month low of $0.63 and a 12-month high of $3.23. The company has a fifty day moving average price of $0.95 and a 200-day moving average price of $1.11. The firm has a market capitalization of $43.19 million, a PE ratio of -4.59 and a beta of 0.46.

Estrella Immunopharma (NASDAQ:ESLA) last posted its quarterly earnings results on Friday, September 27th. The company reported ($0.13) EPS for the quarter.

Estrella Immunopharma Company Profile

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia.